Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Michael R. Green, Sattva S. Neelapu et al.|Nature Medicine|2020Cited by 593
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|The Lancet Oncology|2012Cited by 411
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Mansoor Noorani et al.|British Journal of Haematology|2014Cited by 364
Non-Hodgkin’s LymphomasAndrew D. Zelenetz, Furhan Yunus, Jeremy S. Abramson et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 329
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263